Ulixacaltamide hydrochloride is under clinical development by Praxis Precision Medicines and currently in Phase III for Essential Tremor. According to GlobalData, Phase III drugs for Essential Tremor does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ulixacaltamide hydrochloride LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ulixacaltamide hydrochloride overview

Ulixacaltamide hydrochloride (PRAX-944) is under development for the treatment of essential tremor and Parkinson’s disease. The drug candidate is administered through oral route in the form of tablet. It acts by targeting the T-type calcium channel. It was also under development for the treatment of absence seizures. It is developed based on CEREBRUM small molecule platform.

Praxis Precision Medicines overview

Praxis Precision Medicines (Praxis) is a clinical-stage biopharmaceutical company that translates genetic insights for the development of novel therapies to treat central nervous system disorders. The company’s pipeline program includes PRAX-114, PRAX-944, PRAXIS-050 and PRAXIS-040 which are molecule GABA receptors for the treatment of psychiatry and movement disorders. Praxis provides programs such as PRAX-562, PRAX-222, PRAX-020, SCN2A-LCF, SYNGAP1, PCDH19, and PRAXIS-030 are used for the treatment of genetic epilepsies. Praxis is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Ulixacaltamide hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.